Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2014

Open Access 01-12-2014 | Research article

Chemerin and CMKLR1 expression in human arteries and periadventitial fat: a possible role for local chemerin in atherosclerosis?

Authors: Christos G Kostopoulos, Sofia G Spiroglou, John N Varakis, Efstratios Apostolakis, Helen H Papadaki

Published in: BMC Cardiovascular Disorders | Issue 1/2014

Login to get access

Abstract

Background

Depending on their anatomical location, different fat depots have a different capacity to produce bioactive peptides, called adipokines. Adipokines produced by periadventitial fat have been implicated in the pathogenesis of vascular disease, including atherosclerosis. Chemerin is an adipokine with an established role in immunity, adipose tissue function and metabolism, acting in autocrine, paracrine and endocrine manners. We investigated the protein expression of chemerin and its receptor, CMKLR1, in human aortas, coronary vessels and the respective periadventitial adipose tissue and correlated their expression with the presence of atherosclerosis.

Methods

Immunohistochemistry for chemerin and CMKLR1 was performed on human aortic and coronary artery samples including the periadventitial adipose tissue. Aortic and coronary atherosclerotic lesions were assessed using the AHA classification.

Results

Chemerin immunopositivity was noticed in both periadventitial fat depots, in vascular smooth muscle cells and foam cells in atherosclerotic lesions. Periadventitial fat and foam cell chemerin immunopositivity was statistically significantly correlated with the severity of atherosclerosis in both locations. CMKLR1 was expressed in vascular smooth muscle cells and foam cells in aortic and coronary vessels with atherosclerotic lesions. CMKLR1 immunostaining in foam cells was statistically significantly correlated with aortic atherosclerosis.

Conclusions

Our results lend some support to a presumable role of locally produced chemerin in the progression of atherosclerotic lesions, possibly acting through its CMKLR1 receptor. Further research will elucidate the role of chemerin signaling in atherosclerosis.

Literature
  1. Ronti T, Lupattelli G, Mannarino E: The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf). 2006, 64 (4): 355-365.
  2. Gustafson B: Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb. 2010, 17 (4): 332-341. 10.5551/jat.3939.View ArticlePubMed
  3. Chaldakov GN, Beltowsky J, Ghenev PI, Fiore M, Panayotov P, Rančič G, Aloe L: Adipoparacrinology – vascular periadventitial adipose tissue (tunica adiposa) as an example. Cell Biol Int. 2012, 36 (3): 327-330. 10.1042/CBI20110422.View ArticlePubMed
  4. Ouwens DM, Sell H, Greulich S, Eckel J: The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease. J Cell Mol Med. 2010, 14 (9): 2223-2234. 10.1111/j.1582-4934.2010.01141.x.View ArticlePubMedPubMed Central
  5. Verhagen SN, Visseren FL: Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis. 2011, 214 (1): 3-10. 10.1016/j.atherosclerosis.2010.05.034.View ArticlePubMed
  6. Yamawaki H: Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull. 2011, 34 (3): 307-310. 10.1248/bpb.34.307.View ArticlePubMed
  7. Yudkin JS, Eringa E, Stehouwer CD: "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005, 365 (9473): 1817-1820. 10.1016/S0140-6736(05)66585-3.View ArticlePubMed
  8. Iacobellis G, Bianco AC: Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab. 2011, 22 (11): 450-457. 10.1016/j.tem.2011.07.003.View ArticlePubMed
  9. Szasz T, Webb RC: Perivascular adipose tissue: more than just structural support. Clin Sci (Lond). 2012, 122 (1): 1-12. 10.1042/CS20110151.View Article
  10. Xu A, Wang Y, Lam KS, Vanhoutte PM: Vascular actions of adipokines molecular mechanisms and therapeutic implications. Adv Pharmacol. 2010, 60: 229-255.View ArticlePubMed
  11. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, Brézillon S, Tyldesley R, Blanpain C, Detheux M, Mantovani A, Sozzani S, Vassart G, Parmentier M, Communi D: Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003, 198 (7): 977-985. 10.1084/jem.20030382.View ArticlePubMedPubMed Central
  12. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S, Sinal CJ: Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007, 282 (38): 28175-28188. 10.1074/jbc.M700793200.View ArticlePubMed
  13. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D: Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007, 148 (10): 4687-4694. 10.1210/en.2007-0175.View ArticlePubMed
  14. Bondue B, Wittamer V, Parmentier M: Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. 2011, 22 (5–6): 331-338.View ArticlePubMed
  15. Dong B, Ji W, Zhang Y: Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med. 2011, 50 (10): 1093-1097. 10.2169/internalmedicine.50.5025.View ArticlePubMed
  16. Gao X, Mi S, Zhang F, Gong F, Lai Y, Gao F, Zhang X, Wang L, Tao H: Association of chemerin mRNA expression in human epicardial adipose tissue with coronary atherosclerosis. Cardiovasc Diabetol. 2011, 10: 87-10.1186/1475-2840-10-87.View ArticlePubMedPubMed Central
  17. Landgraf K, Friebe D, Ullrich T, Kratzsch J, Dittrich K, Herberth G, Adams V, Kiess W, Erbs S, Körner A: Chemerin as a mediator between obesity and vascular inflammation in children. J Clin Endocrinol Metab. 2012, 97 (4): E556-E564. 10.1210/jc.2011-2937.View ArticlePubMed
  18. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000, 20 (5): 1262-1275. 10.1161/01.ATV.20.5.1262.View ArticlePubMed
  19. Spiroglou SG, Kostopoulos CG, Varakis JN, Papadaki HH: Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J Atheroscler Thromb. 2010, 17 (2): 115-130. 10.5551/jat.1735.View ArticlePubMed
  20. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA: Increased Chemerin and Decreased Omentin-1 in Both Adipose Tissue and Plasma in Nascent Metabolic Syndrome. J Clin Endocrinol Metab. 2013, 98 (3): E514-E517. 10.1210/jc.2012-3673.View ArticlePubMed
  21. Hart R, Greaves DR: Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5. J Immunol. 2010, 185 (6): 3728-3739. 10.4049/jimmunol.0902154.View ArticlePubMed
  22. Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R, Creager MA, Serhan CN, Conte MS: Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol. 2010, 177 (4): 2116-2123. 10.2353/ajpath.2010.091082.View ArticlePubMedPubMed Central
  23. Kaur J, Adya R, Tan BK, Chen J, Randeva HS: Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun. 2010, 391 (4): 1762-1768. 10.1016/j.bbrc.2009.12.150.View ArticlePubMed
  24. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN: Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol. 2007, 178 (6): 3912-3917. 10.4049/jimmunol.178.6.3912.View ArticlePubMed
  25. Bondue B, De Henau O, Luangsay S, Devosse T, de Nadaï P, Springael JY, Parmentier M, Vosters O: The chemerin/ChemR23 system does not affect the pro-inflammatory response of mouse and human macrophages ex vivo. PLoS One. 2012, 7 (6): e40043-10.1371/journal.pone.0040043.View ArticlePubMedPubMed Central
  26. Zhao RJ, Wang H: Chemerin/ChemR23 signaling axis is involved in the endothelial protection by K(ATP) channel opener iptakalim. Acta Pharmacol Sin. 2011, 32 (5): 573-580. 10.1038/aps.2011.19.View ArticlePubMedPubMed Central
  27. Monnier J, Lewén S, O'Hara E, Huang K, Tu H, Butcher EC, Zabel BA: Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells. J Immunol. 2012, 189 (2): 956-967. 10.4049/jimmunol.1102871.View ArticlePubMedPubMed Central
  28. Xiaotao L, Xiaoxia Z, Yue X, Liye W: Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis. 2012, 23 (6): 412-416. 10.1097/MCA.0b013e3283576a60.View ArticlePubMed
  29. Yoo HJ, Choi HY, Yang SJ, Kim HY, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH: Circulating chemerin level is independently correlated with arterial stiffness. J Atheroscler Thromb. 2012, 19 (1): 59-68. 10.5551/jat.9647.View ArticlePubMed
  30. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, Lebherz C, Tittus J, Reiser M, Becker C, Göke B, Leber AW, Parhofer KG, Broedl UC: Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009, 161 (2): 339-344. 10.1530/EJE-09-0380.View ArticlePubMed
  31. Neves KB, Lobato NS, Lopes RA, Filgueira FP, Zanotto CZ, Oliveira AM, Tostes RC: Chemerin reduces vascular nitric oxide ‒ cyclic guanosine monophosphate signaling: a link to vascular dysfunction in obesity?. Clin Sci (Lond). 2014, 127 (2): 111-122. 10.1042/CS20130286.View Article
    1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2261/​14/​56/​prepub
Metadata
Title
Chemerin and CMKLR1 expression in human arteries and periadventitial fat: a possible role for local chemerin in atherosclerosis?
Authors
Christos G Kostopoulos
Sofia G Spiroglou
John N Varakis
Efstratios Apostolakis
Helen H Papadaki
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2014
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/1471-2261-14-56

Other articles of this Issue 1/2014

BMC Cardiovascular Disorders 1/2014 Go to the issue

Research article

Left ventricular filling pressure assessed by exercise TDI was correlated with early HFNEF in patients with non-obstructive hypertrophic cardiomyopathy

Research article

Sex-dependent association between coronary vessel dominance and cardiac syndrome X: a case-control study

Research article

Aspirin use and knowledge in the community: a population- and health facility based survey for measuring local health system performance

Research article

Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital discharge

Research article

Treatment patterns and their outcomes of acute aortic intramural hematoma in real world: multicenter registry for aortic intramural hematoma

Research article

Simvastatin down-regulates the production of Interleukin-8 by neutrophil leukocytes from dyslipidemic patients

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits